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Abstract
The objective of this work was to assess the convergent validity
of a previously developed rheumatoid arthritis medical records-
based index of severity (RARBIS) by comparing it with the 28-
joint Disease Activity Score (DAS28). This study was
conducted in subjects within the Brigham and Women's
Hospital Rheumatoid Arthritis Sequential Study (BRASS). We
selected 100 patients with rheumatoid arthritis (RA) from the
BRASS with DAS28 scores equally distributed in four quartiles.
The medical records were reviewed to calculate the RARBIS,
which includes indicators from the following categories: prior
surgical history, radiologic and laboratory findings, clinical and
functional status, and extra-articular manifestations. The
Spearman correlation between the RARBIS and the DAS28
was assessed in the total study population and in relevant
subgroups. We re-weighted on subscales and recalculated the
RARBIS score. This was performed based on findings of
correlations between the DAS28 and subscales; and also the
result from a multiple linear regression with the DAS28 (as a
dependent variable) and five subscales (as independent
variables). The mean RARBIS was 4.36 (range 0–11). Among
the total study cohort, the RARBIS was moderately correlated
with the DAS28 (r = 0.41, 95% confidence interval [CI] 0.23–
0.56). In subgroup analyses, including age, gender, rheumatoid
factor status, and disease duration, we found no statistically
significant differences in the correlations. After re-weighting, the
correlation between the RARBIS and the DAS28 was
somewhat improved (r  = 0.48, 95% CI 0.31–0.62). In
conclusion, the RARBIS correlated moderately well with the
DAS28 in this population. The RARBIS has both face and
convergent validity for patients with RA and relevant subgroups
and may have application for medical records studies in patients
with RA.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
that can lead to long-term joint damage resulting in chronic
pain, loss of function, and disability [1]. It causes substantial
morbidity in most patients and premature mortality in many [2-
5]. Some patients with severe RA may be at higher risk for
complications such as infection, gastrointestinal problems,
heart disease, and cancer [6,7]. However, those complica-
tions may be related to adverse effects of drug therapies rather
than to the effect of RA.
Several studies have reported serious but rare adverse effects
of RA medications. For example, biologic agents that block the
action of tumor necrosis factor-α have been investigated as
the cause of serious infections, hematological cancers, and
demyelinating disease [8-11]. Lymphoproliferative malignan-
cies among users of disease modifying anti-rheumatic drugs
have also been reported [12,13].
Data on adverse drug events come predominantly from clinical
trials, case reports, case series, and epidemiologic studies.
BRASS = Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study; CI = confidence interval; DAS28 = 28-joint Disease Activity Score; 
ESR = erythrocyte sedimentation rate; RA = rheumatoid arthritis; RARBIS = rheumatoid arthritis medical records-based index of severity; SD = stand-
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Randomized clinical trials are limited in their ability to detect
rare adverse effects because of small sample size, selection of
patients least likely to experience toxicity, and short duration of
follow-up. It is difficult to base causality assessment on case
reports/series. Therefore, pharmacoepidemiologic studies can
play a pivotal role in evaluating safety of medications used in
RA. However, the severity of RA may affect the choice of med-
ication and RA outcomes. Failing to control for RA severity in
epidemiologic studies may lead to biased estimates of the
association between RA drug treatment and RA outcomes.
This type of bias, confounding by indication, is an important
potential bias in many pharmacoepidemiologic studies
[14,15].
To measure RA disease severity in medical records, we
defined a set of indicators of severe RA through an expert Del-
phi panel of rheumatologists [16]. On the basis of their find-
ings, we developed an RA medical records-based index of
severity (RARBIS) [17]. The goal of this project was to test the
convergent validity of the RARBIS with another accepted RA
measure. However, there is no standard criteria for RA severity
that can be assessed from medical records.
Although disease activity and disease severity are not synony-
mous, we decided the correlation of the RARBIS with the 28-
joint Disease Activity Score (DAS28), a widely used instru-
ment that affects treatment decisions by rheumatologists in
daily clinical practice. The DAS28 is a statistically derived
index consisting of number of swollen joints, number of tender
joints, erythrocyte sedimentation rate (ESR), and general
health [18,19]. Thus, recognizing the methodologic limitations
of this approach, we chose to assess the convergent validity
of the RARBIS by comparing it with the DAS28, a well
accepted RA disease index.
Materials and methods
Study population
The Brigham and Women's Hospital Rheumatoid Arthritis
Sequential Study (BRASS) is a cohort of patients with con-
firmed RA who receive care from rheumatologists in the Divi-
sion of Rheumatology, Immunology and Allergy at our hospital.
Every six months, patients are asked to complete question-
naires regarding general health information, medications for
RA, health status, and surgical history for RA. Clinicians com-
plete a similar questionnaire, including global assessment and
joint counts. For our study, patients were identified from the
BRASS cohort between March and October 2003. Identified
patients during the study period were partitioned in quartiles
based on their baseline DAS28 scores. We randomly selected
100 RA patients with the baseline DAS28 equally distributed
in four quartiles.
RARBIS
The RARBIS was developed through an expert Delphi panel of
six rheumatologists, and convergent validity was assessed by
comparing it with intensity of the actual RA treatments that
patients received [16,17] (Table 1.) The index includes indica-
tors from five categories: prior surgical history (C1–C2 fusion
and joint surgeries), radiologic findings (C1–C2 subluxation
and erosions), laboratory findings (rheumatoid factor status,
ESR, C-reactive protein, and platelet counts), clinical and
functional status (arthritis flares, morning stiffness, physician
global rating, and functional status), and extra-articular mani-
festations (vasculitis and pulmonary nodule). These indicators
are available in medical records. The total RARBIS score was
calculated by summing the five subscales. Because joint
Table 1
Rheumatoid arthritis severity index
Subscale Points
Surgery subscale:
C1–C2 fusion 3 points
Any hand joint 1 point
Any foot joint 1 point
Major joints 1 point each
(hips, knees, shoulder, elbow, wrist, ankle) (maximum of 2)
Maximum score for category: 5 points
X-ray subscale:
C1–C2 subluxation 3 points
Any erosions 1 point
Maximum score for category: 4 points
Extra-articular manifestations subscale:
Vasculitis 1 point
Pulmonary lung nodule 1 point
Maximum score for category: 1 point
Clinical status subscale:
Arthritis flares
11  p o i n t
2–4 2 points
5+ 3 points
Worst physician global rating: "doing poor" 2 points
Functional status
Unable to do hobbies 1 point
Unable to work 2 points
Unable to care for self 3 points
Hours of morning stiffness <1 0 points
Summed points in each category must not exceed the maximum 
score for the category. For example, a patient could have 10 points in 
the clinical status subscale but would be assigned the maximum for 
that category (3 points).Available online http://arthritis-research.com/content/8/3/R57
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destructions and surgical histories were considered by the
Delphi panel to be indicators strongly associated with severe
RA, the prior surgical and radiologic subscales were given
higher weights in the total RARBIS score. The surgical sub-
scale and radiologic subscale account for 60% of the total
RARBIS score. The RARBIS score with medication use was
also calculated with the addition of data on medication use.
Data collection and processing
Electronic medical records were reviewed to collect informa-
tion on demographic characteristics, clinical and functional
status, laboratory test results, and radiology reports. Data on
clinical status indicators and laboratory test results were col-
lected for one year prior to baseline. If a patient's clinical and
functional status changed during that period, the worst condi-
tion was recorded. When there was an expression indicating
disease activity such as "flare up," "ongoing," and "active" in
medical records, we counted it as having a flare. The number
of flares in the last year was summed. If there was no informa-
tion regarding clinical and functional status on the medical
chart, we assumed a patient had no apparent clinical and func-
tional manifestations during that period. The value associated
Table 2
Characteristics of patients with rheumatoid arthritis (n = 100)
Characteristics Number of Patients
Age, mean (SD (range)), years 59 (13.3 (25–86))
Age diagnosed for RA, mean (SD (range)), years 43 (14.3 (16–78))
Duration of RA, mean (SD (range)), years 15 (11.9 (0–50))
Number of rheumatology visits in last year, mean (SD (range)) 4.5 (2.0 (1–12))
DAS28, mean (SD (range)) 4.2 (1.6 (1.3–7.7))
Female gender 81 (81)
Highest level of education: > high school 96 (96)
Physician global rating: poor 11 (11)
Hospitalized for RA in last year: yes 3 (3)
ACR Functional Classification* (worst in last year)
Class I (no limitation) 33 (33)
Class II (self-care, working, no hobbies) 2 (2)
Class III (self-care, not working, no hobbies) 5 (5)
Class IV (limited self-care, bed-bound) 6 (6)
Hours of morning stiffness† (worst in last year), hr
< 1 73 (73)
1 to 4 23 (23)
> 4 4 (4)
Number of flares in last year‡
0 38 (38)
1 30 (30)
1 to 4 29 (29)
> 5 3 (3)
Pulmonary nodule¶: ever 5 (5)
Vasculitis: ever 0 (0)
Joint erosion¶: ever 70 (70)
*Fifty-four patients had undefined ACR Functional Classification based on chart review.
†No record of morning stiffness in the medical record was counted as <1 hour.
‡No record of flares in the medical record was counted as no flares (zero).
¶ Missing data were assumed to be the absence of the extra-articular manifestation for pulmonary nodule. When radiologic and laboratory data 
were not available, the data was considered as missing. ACR, American College of Rheumatology; DAS28, 28-joint Disease Activity Score; RA, 
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with the most severe disease activity in the preceding year was
recorded. Whether patients ever had any erosions and C1–
C2 subluxation was examined in radiology reports. We
obtained information on surgical history, extra-articular mani-
festations, physician's global assessment of arthritis activity,
and medication use from a questionnaire at baseline in
BRASS, which was completed by patients and physicians. If
data were missing on radiology findings, laboratory tests, sur-
gical history, or extra-articular manifestations, we assumed
that no clinical information or radiologic/laboratory reports
suggested that patients did not havesignificant RA symptoms
at that time. The study was approved by the Institutional
Review Board of Partners HealthCare (Boston, MA, USA).
Statistical analysis
To test the convergent validity of RARBIS as a measure of dis-
ease severity, the Spearman rank correlation between the
RARBIS and the DAS28 was assessed in the total study pop-
ulation and in relevant subgroups, including age, gender, rheu-
matoid factor status, and disease duration. To examine
whether different subscale weights improved the performance
of the index, we re-weighted subscales and recalculated the
RARBIS score. The original weights of the RARBIS were
determined based on the finding of the Delphi panel rating
[16]. The surgical subscale was weighted more than the clini-
cal subscale. The new weights were derived from the correla-
tions between the DAS28 and subscales and the result from
a multiple linear regression with the DAS28 as a dependent
variable. Because clinical indicators and radiologic indicators
were closely correlated with the DAS28 and the surgical his-
tory was not correlated with the DAS28, we up-weighted the
clinical subscale and down-weighted the surgical subscale.
Three different weighting systems included: exchanging the
maximum scores of the clinical status subscale and the sur-
gery subscale; up-weighting the clinical status subscale by a
factor of two and removing the surgery subscale and the extra-
articular manifestation subscale; multiplying each subscale by
the regression coefficients of a linear regression of all sub-
scales on the DAS28.
Results
Patients characteristics and the RARBIS score
Patient characteristics of the study cohort are summarized in
Table 2. The mean age of patients was 59 years with the
majority less than 65 years. Most of the patients were female
(81%) with mean disease duration of 16 years. The mean
value of the DAS28 was 4.2 (standard deviation [SD] 1.6) at
baseline. The mean total RARBIS score calculated for all
patients was 4.36 (SD 2.37, range 0–11) (Figure 1). The dis-
tributions of each subscale and total score are shown in Table
3. The mean of the clinical subscale was 1.43 (SD 1.20) with
a range of 0–3. Patients in the study had few surgeries, few
extra-articular manifestations, and low scores on the radiology
subscale.
Comparisons of the RARBIS with the DAS28
Table 4 shows the Spearman correlation with 95% confidence
interval (CI) between the RARBIS and the DAS28. The total
score was moderately correlated with the DAS28 (r = 0.41,
95% CI 0.23–0.56). Figure 2 shows scatter plots of the paired
RARBIS scores and corresponding DAS28 scores. Two com-
ponents of the total score, the clinical subscale and the X-ray
subscale, were significantly related to the DAS28. The labora-
tory subscale had a weak correlation with the DAS28. The
other components were not correlated with the DAS28. When
the subscale of medication use was added to the RARBIS, the
score was also significantly correlated with the DAS28,
though the correlation was attenuated.
Correlations between the DAS28 and the RARBIS among
subgroups are shown in Table 5. In subgroup analyses, we
found no statistically significant differences between the sub-
Figure 2
Scatter plot of the rheumatoid arthritis medical records-based index of  severity (RARBIS) versus the 28-joint Disease Activity Score 28  (DAS28) Scatter plot of the rheumatoid arthritis medical records-based index of 
severity (RARBIS) versus the 28-joint Disease Activity Score 28 
(DAS28).
Figure 1
Frequency distribution of the rheumatoid arthritis medical records- based index of severity (RARBIS) Frequency distribution of the rheumatoid arthritis medical records-
based index of severity (RARBIS).Available online http://arthritis-research.com/content/8/3/R57
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groups in their correlations between the DAS28 and the RAR-
BIS. However, the sample size in each subgroup was small.
Re-weighting
Up-weighting on the clinical subscale and down-weighting on
the surgical subscale slightly improved the correlation with the
DAS28. Different weights did not make large differences in
correlation between the RARBIS and the DAS28 (Table 6).
Discussion
The results of our study provide support for the convergent
validity of the RARBIS with the DAS28. We are hopeful that
the RARBIS can be used to help define RA severity but recog-
nize that there are no well accepted measures of RA severity,
making validation quite a challenge. RA severity is considered
a complex measure determined by objective components such
as disease activity (for example, tender/swollen joints and
acute-phase reactants) and physical damage (for example,
radiologic damage, and functional disability) and subjective
components (for example, global health assessment, pain, grip
strength, fatigue, and costs) [20,21]. We chose to use the
Table 5
Correlations between the DAS28 and the total RARBIS score 
among subgroups
Subgroup Spearman 95% CI p value*
Age 0.51
< 65 years (n = 65) 0.45 0.23 – 0.63
≥ 65 years (n = 35) 0.33 0.00 – 0.60
Gender 0.40
Male (n = 19) 0.52 0.09 – 0.79
Female (n = 81) 0.35 0.14 – 0.53
Rheumatoid factor 0.69
Negative (n = 27) 0.51 0.16 – 0.75
Positive (n = 67) 0.44 0.23 – 0.62
Duration of RA 0.96
< 5 years (n = 19) 0.35 -0.13 – 0.69
≥5 years (n = 81) 0.37 0.16 – 0.54
* p value for differences between subgroup correlations
CI, confidence interval; DAS28, 28-joint Disease Activity Score; RA, 
rheumatoid arthritis; RARBIS, rheumatoid arthritis medical records-
based index of severity.
Table 3
Distributions of subscales and total scores
Possible maximum Mean (SD) Observed minimum Median Observed maximum
Total RARBIS score 15 4.36 (2.37) 0 4.00 11
Subscale:
Clinical 3 1.43 (1.20) 0 1.00 3
Surgery 5 0.57 (1.00) 0 0.00 5
X-ray 4 1.00(1.07) 0 1.00 4
Extra-articular 
manifestations
1 0.05 (0.22) 0 0.00 1
Laboratory 2 1.31 (0.63) 0 1.00 2
Medication 3 2.00 (1.06) 0 2.00 3
Total score with 
medication
18 6.36 (2.73) 1 6.00 14
The total RARBIS score excludes the medication subscale and was calculated by summing the clinical, surgery, X-ray, extra-articular 
manifestation, and laboratory subscales. The observed minimum scores were zero for each subscale and the total RARBIS (without medications). 
However, when the medication subscale is included in the total score, we did not observe any patients with zero points. SD, standard deviation.
Table 4
Spearman's rank correlation of the total RARBIS score with the 
DAS28
Score Spearman 95% CI p value*
Total RARBIS score 0.41 0.23 – 0.56 <0.0001
Subscales:
Clinical subscale 0.42 0.24 – 0.57 <0.0001
Surgery subscale 0.09 -0.11 – 0.28 0.3690
X-ray subscale 0.34 0.15 – 0.50 0.0005
Extra-articluar subscale 0.002 -0.19 – 0.20 0.9875
Laboratory subscale 0.12 -0.09 – 0.30 0.2890
Medication subscale -0.01 -0.21 – 0.18 0.8860
Total score with medication 0.33 0.14 – 0.49 0.0007
* p value for correlations
The total RARBIS score excludes the medication subscale and was 
calculated by summing the clinical, surgery, X-ray, extra-articular 
manifestation, and laboratory subscales. CI, confidence interval; 
DAS28, 28-joint Disease Activity Score; RARBIS, rheumatoid 
arthritis medical records-based index of severity.Arthritis Research & Therapy    Vol 8 No 3    Sato et al.
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DAS28, a measure of disease activity, because it is commonly
used for therapeutic decision-making.
Symmons and colleagues [22] developed a measure of overall
status in RA composed of demographic details, activity score,
damage score, and drug treatments [23]. Bardwell and col-
leagues [24] reported a brief measure of severity for RA based
on physician's rating of disease activity, functional impairment,
and physical damage. Navarro-Cano and colleagues [25]
measured RA disease severity using an RA component of the
Duke Severity of Illness Checklist through a physician's
assessment. A measure of RA functional status based on
American College of Rheumatology standards [26] involves
clinical assessment (for example, physical examination), labo-
ratory tests (for example, ESR), and imaging procedures (for
example, X-rays and magnetic resonance imaging), which may
be the most accurate measure of RA severity. Unlike those
measures, the RARBIS does not require a new physician's
assessment and the information on indicators can be routinely
collected from typical medical records. Thus, the RARBIS may
have great utility for researchers using medical records.
The present study has several limitations. As we fully recognize
and have noted, because there is no standard RA severity
measure, we assessed the convergent, and not the criterion,
validity of our index by comparing it with the DAS28. We
assumed that the DAS28 should be highly correlated with RA
severity because disease activity is deemed one of the core
determinants of RA disease severity and the DAS28 includes
patient-reported disease status. To enhance information for
the RARBIS, we obtained information on surgical history,
extra-articular manifestations, and physician's global assess-
ment of arthritis activity from a questionnaire at baseline in
BRASS. This modification did not change the properties of the
index score in the present study.
Conclusion
We have examined the convergent validity of a medical
records-based index of RA severity, the RARBIS. It is obtained
simply by forming an arithmetic sum of indicators on a medical
record. We propose it as a practical and useful tool for meas-
uring RA severity. Because the RARBIS does not require a
physician's assessment for its calculation, it is easily applied
retrospectively to medical records. All of the data for the RAR-
BIS are accessible from medical records. The ease of collect-
ing these data is greatly enhanced by an integrated medical
record that contains all laboratory, radiologic, and surgical
information. In studies that assess associations between treat-
ments and RA outcomes, the RARBIS will be useful to control
for confounding by RA severity. Before our index can be rec-
ommended, it would be beneficial to further evaluate it in other
populations as well as use other gold standards.
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